KB-1134-01

Zolbetuximab

12143

Background of Zolbetuximab

Zolbetuximab, also named MAb362, is a novel chimeric IgG1 antibody highly specific for claudin 18.2. It is produced in Chinese Hamster Ovary (CHO) cells by standard recombinant expression technology. It binds to claudin 18.2 on the tumor cell surface to stimulate cellular and soluble immune effectors that activate antibody-dependent cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). It can also induce apoptosis and inhibit cell proliferation.

Specifications

Catalog Number	KB-1134-01
Antibody Name	Zolbetuximab
Isotype	Human-IgG1, kappa
Target	CLDN18.2
Species Reactivity	Human
Host Cell Line	EXPI-CHO
Purification Method	Affinity purified
Concentration	>2mg/mL
Formulation	20mM sodium citrate,150mM NaCl, pH5.5
Purity	>95% by SDS-PAGE and SEC-SEC-HPLC
Validation	SDS-PAGE \| SEC-HPLC \| FACS
Endotoxin Level	<0.5 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Micke, Patrick, Johanna Sofia Margareta Mattsson, Karolina Edlund, Miriam Lohr, Karin Jirstro?m, Anders Berglund, Johan Botling, et al. 2014. ¡ùAberrantly Activated Claudin 6 and 18.2 as Potential Therapy Targets in Non-Small-Cell Lung Cancer.¡ì International Journal of Cancer 135 (9): 2206Ã¿14. doi:10.1002/ijc.28857.
Singh, Prabhsimranjot, Sudhamshi Toom, and Yiwu Huang. 2017. ¡ùAnti-Claudin 18.2 Antibody as New Targeted Therapy for Advanced Gastric Cancer,¡ì May. Journal of Hematology & Oncology, 1Ã¿5. doi:10.1186/s13045-017- 0473-4.
Sahin, U, M Koslowski, K Dhaene, D Usener, G Brandenburg, G Seitz, C Huber, and O Tureci. 2008. ¡ùClaudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development.¡ì Clinical Cancer Research 14 (23): 7624Ã¿34. doi:10.1158/1078-0432.CCR-08-1547.